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Abstract
The FANCA gene is one of the genes in which mutations lead to Fanconi anaemia, a rare autosomal
recessive disorder characterised by congenital abnormalities, bone marrow failure, and
predisposition to malignancy. FANCA is also a potential breast and ovarian cancer susceptibility
gene. A novel allele was identified which has a tandem duplication of a 13 base pair sequence in the
promoter region.
Methods: We screened germline DNA from 352 breast cancer patients, 390 ovarian cancer
patients and 256 normal controls to determine if the presence of either of these two alleles was
associated with an increased risk of breast or ovarian cancer.
Results: The duplication allele had a frequency of 0.34 in the normal controls. There was a non-
significant decrease in the frequency of the duplication allele in breast cancer patients. The
frequency of the duplication allele was significantly decreased in ovarian cancer patients. However,
when malignant and benign tumours were considered separately, the decrease was only significant
in benign tumours.
Conclusion: The allele with the tandem duplication does not appear to modify breast cancer risk
but may act as a low penetrance protective allele for ovarian cancer.
Background
Fanconi anaemia is a rare autosomal recessive disorder
characterised by congenital abnormalities, progressive
bone marrow failure, and predisposition to acute myelog-
enous leukemia and other malignancies. At the cellular
level, the disease is characterised by an inability to repair
cross-linked DNA [1]. There are multiple genes in which
mutations can give rise to Fanconi anaemia.
The FANCA gene is defective in more than 65% of Fan-
coni anaemia cases. FANCA and five other Fanconi anae-
mia genes code for components of a complex that is
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required for the ubiquitination of FANCD2 in response to
DNA damage. Ubiquitinated FANCD2 is targeted to
nuclear foci of DNA repair proteins including BRCA1 and
RAD51 (reviewed in [2]). The complex also interacts
directly with the FANCD1 protein [3]), now known to be
the product of the breast and ovarian cancer predisposi-
tion gene, BRCA2  [4]. As individuals heterozygous for
BRCA2 mutations have a high lifetime risk of acquiring
breast and ovarian cancer, it is likely that alterations in
other Fanconi anaemia genes might be associated with an
increased risk of breast and ovarian cancer.
In human breast and ovarian cancers, recurrent loss of
heterozygosity has been shown to occur on the long arm
of chromosome 16 [5,6] and is localised to 16q24.3 [7-9].
This suggests the presence of one or more tumour sup-
pressor genes in this region. However, no recurrent
tumour-specific mutations in any of the 16q24.3 candi-
date tumour suppressor genes assessed for mutations have
been reported in breast tumours (e.g. [10-12]).
FANCA  localises to 16q24.3 [13] and is a plausible
tumour suppressor gene candidate because of its role in
the repair of DNA damage. Cleton-Jansen et al [14] did
not detect any mutations in 19 cases of breast cancer with
16q24.3 loss of heterozygosity and concluded that
FANCA was not the tumour suppressor gene underlying
16q24.3 loss of heterozygosity. Nevertheless, FANCA
remains an attractive candidate as either a cancer predis-
position gene or a target of genetic or epigenetic inactiva-
tion in sporadic tumours.
While screening the FANCA promoter region by single
strand conformation analysis, we identified a polymor-
phism in the FANCA promoter region. As promoter poly-
morphisms can alter the transcription or regulation of a
gene, we sought to determine whether one of these two
alleles might be associated with an altered risk of develop-
ing breast or ovarian cancer.
Methods
Subjects
All breast cancer cases were systematically ascertained
through breast clinics in the Wessex region of southern
England as described previously [15,16] These cases were
selected on the basis of an age at onset under 40 years, a
family history of breast/ovarian cancer (defined as two or
more cases of breast/ovarian cancer in a first or second
degree female relative) or bilateral breast cancer irrespec-
tive of family history or age at onset. Family histories were
verified as far as possible from medical records and death
certificates. Blood was taken from all recruits who con-
sented to molecular analysis for breast cancer predisposi-
tion genes. The age range of the breast cancer participants
was 19–76 with a mean age of 40 years
Details of the ovarian tumour cases have been described
previously [17,18]. Briefly, cases of ovarian tumours were
ascertained from women undergoing primary surgery in
hospitals from southern England between 1993–1998. A
specialist gynaecological pathologist confirmed the histo-
logical diagnosis for each tumour. A total of 390 ovarian
tumours were included in the study consisting of 313
malignant (127 serous, 82 endometrioid, 42 mucinous,
13 clear cell, 49 undifferentiated adenocarcinomas), 15
borderline tumours (11 mucinous, 4 serous) and 62
benign tumours (18 fibromas, 26 serous, 18 mucinous).
The age range of the ovarian cancer patients was 23–90
with a mean of 62 years.
The controls represent the population from which the
cases arose and consisted of 256 Caucasian female volun-
teers who were either patients attending for non-neoplas-
tic disease conditions or staff at the Princess Anne
Hospital, Southampton. The age of the controls ranged
from 18 – 84 with a mean age of 39 years. Both control
and cancer groups were drawn from the same geographi-
cal area. Epidemiological data such as reproductive fac-
tors, oral contraceptive use, smoking and obesity were not
available for any of the cancer or control groups. We have
obtained approval for this research from the appropriate
ethics committees and are in compliance with the Hel-
sinki Declaration.
Molecular genetic analysis
DNA for genotyping was prepared from the peripheral
blood samples of patients and controls. The region con-
taining the duplication was amplified using the primers
5'CCAAACGCAAAAACTACCTCACCG3' and
5'CGCTGCCTTCCTATTGGCTGC3'. Fifty ng of DNA was
used in a 25 µl reaction using 0.5 U HotStarTaq (Qiagen,
Hilden, Germany), 200 nM of each of the primers, 800
µM total nucleotides in the buffer supplied by the manu-
facturer (Qiagen) and 1.5x Q solution (Qiagen). Cycling
conditions were 15 min at 95°C, 11 cycles of 95°C/45 s,
60°-50°C/45 s (decreasing by 1°C per cycle), 72°C/45 s,
followed by 34 cycles of 95°C/45 s, 50°C/45 s, 72°C/45
s and finally 10 min at 72°C. The PCR primers amplified
a 151 base pair product for allele 1 and a 164 base pair
product for allele 2. The products were separated by elec-
trophoresis on 3% agarose gels. PCR products from the
three genotypes were sequenced on the ABI Prism 3100
Genetic Analyser (Applied Biosystems, Foster City, CA)
using BigDye Terminator v3.1 chemistry (Applied
Biosystems).
Statistical analysis
The Hardy-Weinberg equilibrium was assessed by the
standard methods. The data were considered using mod-
els assuming dominant inheritance (i.e., women with one
or two duplication alleles had the same relative hazard),BMC Cancer 2005, 5:43 http://www.biomedcentral.com/1471-2407/5/43
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codominant inheritance (i.e., the relative hazard differed
between women with one duplication allele compared
with those with two duplication alleles), or recessive
inheritance (i.e., only women with two duplication alleles
were at increased risk). For all analyses, the control sub-
jects were treated as a single group without stratification.
Fisher's Exact test using Instat 3.01 software (Graphpad
Software) was used to calculate the significance (p value)
and odds ratio (OR) with a 95% confidence interval. All
statistical calculations were two-sided and p values were
considered statistically significant when less than 0.05.
Results
Identification of the FANCA promoter polymorphism
We identified a polymorphism in the FANCA promoter
region using single strand conformation analysis. Variant
bands were purified by PCR amplification from a band
stab and sequenced in both directions directly from the
PCR product. Comparison of the sequences obtained for
each band and the sequence of the FANCA  promoter
(Genbank Accession AC005360) showed that the varia-
tion in the patterns was due to the presence of either a sin-
gle or duplicated 13 base pair sequence.
The 13 base pair sequence is located at -98 to -110 bases
upstream of the beginning of transcription as defined by
the NCBI reference sequence for FANCA (NM 000135.1
23-Dec 2003). The translation start site is 32 base pairs
further downstream (Figure 1). Allele 1 has a single copy
of the sequence GGCCACGACGCAA. Allele 2 has two tan-
demly arranged copies of this sequence. Interestingly, the
sequence immediately downstream of the 13 base pair
sequence, GGCCtCGACctgA shows considerable homol-
ogy to the 13 base pair sequence (divergent nucleotides in
lower case).
Case control study of the FANCA promoter polymorphism
We designed a PCR assay in which both alleles are ampli-
fied simultaneously using a set of primers flanking the
polymorphism (Figure 2). The frequency of the polymor-
phism was determined in breast cancer patients, ovarian
cancer patients and controls to assess if the presence of
either allele was associated with a predisposition to breast
or ovarian cancer.
Table 1 shows the distribution of genotypes in the breast
and ovarian cancer patients and the controls. The distribu-
tion of the genotypes within each of the groups did not
deviate significantly from those expected under Hardy-
Weinberg equilibrium.
The frequency of the duplication allele (allele 2) in the
breast cancer patients was not significantly different from
the controls (0.32 versus 0.34, p = 0.53). The distribution
of genotypes in the breast cancer cases was similar to the
controls. The genotype distribution was similar when
stratifying the breast cancers according to the selection cri-
teria although the frequency of the 12 and 22 genotypes
showed a non-significant elevation among the family his-
tory group.
The frequency of the duplication allele in the ovarian can-
cer patients was 0.29 which was significantly different
from the controls (p = 0.048). In addition, the ovarian
cancer patients had a nominally significant decrease in the
number of 12 and 22 genotype carriers compared to the
controls (p = 0.05) suggesting that the duplication may be
protective for the disease with an odds ratio of 0.72 (95%
CI, 0.53–0.99). All subgroups of the ovarian cancer
patients showed a reduced frequency of 12 and 22 geno-
types, with the exception of patients with borderline
tumours and clear cell carcinomas. However, the number
of cases in these latter categories was very small. Interest-
Sequence of FANCA promoter allele in the polymorphic region Figure 1
Sequence of FANCA promoter allele in the polymorphic region. Allele 1 has a single copy of a 13 base pair sequence. 
This has been defined as GGCCACGACGCAA in accordance with current nomenclature for mutations [21] although it could 
theoretically be GCCACGACGCAAG or CCACGACGCAAGG. Allele 2 has two tandemly arranged copies of this sequence. 
The 13 base pair sequence is located at -98 to -110 bases upstream of the beginning of transcription as defined by the NCBI 
reference sequence NM_000135.1. Exon 1 is in bold and the coding sequence in capitals.
acatGGCCACGACGCAAGGCCACGACGCAAggcctcgacctgaggggcgtggcctggccgccg
ccaacgggtgtgcgcgcctggccgcagccaataggaaggcagcgcgggctcgggcgcagggag
ccgccggggctgtaggcgccaaggccATGTCCGACTCGTGGGTCCCGAACTCCGCCTCGGBMC Cancer 2005, 5:43 http://www.biomedcentral.com/1471-2407/5/43
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ingly, the 62 patients with benign tumours showed a
highly significant decrease in the 12 and 22 genotype fre-
quency (p = .007) with an odds ratio of 0.46 (95% CI
0.26–0.81).
Discussion
The identification of BRCA2 as a member (FANCD1) of
the Fanconi anaemia group of genes has raised the possi-
bility that variation in other Fanconi anaemia genes may
Genotyping the FANCA promoter polymorphism by PCR Figure 2
Genotyping the FANCA promoter polymorphism by PCR. Allele 1 amplifies as a band of 151 base pair, allele 2 as a 
band of 164 base pair. The 3 genotypes are readily distinguishable on a 3 % agarose gel run at 100 V for 1 hour. Homozygous 
samples for both allele 1 and allele 2 are shown as are heterozygous samples which have both bands.
Table 1: The distribution of FANCA promoter polymorphism genotypes in breast and ovarian cancer cases and controls
Study Group No. 11 12 22 12 + 22
n (%) n (%) n (%) n (%) p valuea ORb (95% CI)
Control 256 112 (43.8) 115 (44.9) 29 (11.3) 144 (56.2)
All Breast Cancer 352 164 (46.6) 150 (42.6) 38 (10.8) 188 (53.4) 0.51 0.89 (0.64–1.23)
Diagnosis ≤  40 years 203 104 (51.2) 79 (38.9) 20 (9.9) 99 (48.8) 0.13 0.74 (0.51–1.07
Family History 105 39 (37.1) 53 (50.5) 13 (12.4) 66 (62.9) 0.29 1.32 (0.83–2.10)
Bilateral Disease 44 21 (47.7) 18 (40.9) 5 (11.4) 23 (52.3) 0.63 0.85 (0.45–1.62)
All Ovarian Tumours 390 202 (51.8) 153 (39.2) 35 (9.0) 188 (48.2) 0.05 0.72 (0.53–0.99)
All Malignant 313 157 (50.2) 126 (40.2) 30 (9.6) 156 (49.8) 0.13 0.77 (0.55–1.08)
Serous 127 62 (48.8) 52 (40.9) 13 (10.2) 65 (51.1) 0.38 0.81 (0.53–1.25)
Endometrioid 82 44 (53.6) 29 (35.4) 9 (11.0) 38 (46.4) 0.13 0.67 (0.41–1.11)
Mucinous 42 23 (54.8) 16 (38.1) 3 (7.1) 19 (45.2) 0.24 0.64 (0.33–1.24)
Clear Cell 13 4 (30.8) 8 (61.5) 1 (7.7) 9 (69.2) 0.40 1.75 (0.52–5.83)
Adenocarcinoma 49 24 (49.0) 21 (42.8) 4 (8.2) 25 (51.0) 0.53 0.81 (0.44–1.49)
Borderline 15 6 (40.0) 8 (53.3) 1 (6.7) 9 (60.0) 1.00 1.16 (0.40–3.37)
Benign 62 39 (62.9) 19 (30.6) 4 (6.4) 23 (37.0) 0.007 0.46 (0.26–0.81)
Allele 1 corresponds to the single copy allele, allele 2 corresponds to the duplication allele.
aFisher's exact test (two-sided) for the combined 12/22 genotype frequency using the 11 homozygotes as reference.
bThe odds ratio (OR) and 95% confidence intervals (CI) are shown in parentheses.BMC Cancer 2005, 5:43 http://www.biomedcentral.com/1471-2407/5/43
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predispose to breast or ovarian cancer. The novel 13 base
pair duplication allele identified in this study is of interest
as even single base changes in promoter sequences can
alter regulation of gene expression and contribute to tum-
origenesis, particularly if this affects a transcription factor
binding site (e.g. [19,20]). As both alleles of the FANCA
polymorphism are common, it is unlikely that either
allele would represent a high penetrance predisposition
allele. We therefore undertook a case control study to
determine whether either allele might be responsible for a
more modest increase in the rate of breast and or ovarian
cancer.
Genotyping of the promoter polymorphism in high risk
breast cancer patients showing features of genetic predis-
position revealed no significant difference in the allele or
genotype distribution compared to the normal controls.
The study had 80% power to detect an odds ratio of ≥  1.6
for carriers heterozygous for the duplication and an odds
ratio ≥  1.9 for carriers homozygous for the duplication. As
we could not adjust for known breast cancer risk factors,
we cannot exclude the possibility that confounding fac-
tors may have led to a type II error. However, confounding
due to differences in ethnicity is unlikely as both the cases
and controls were residents of the Southampton area,
which has a predominantly Anglo-Saxon population.
Nevertheless, studies of breast cancer cases selected based
on other clinical characteristics, such as postmenopausal
onset, may be warranted.
Among the ovarian tumour cases, there was a significant
decrease in the frequency of the combined 12 and 22 gen-
otypes, suggesting that allele 2 may protect against ovar-
ian cancer. The trend was particularly evident among the
benign tumours (p = .0007). However, it is possible that
this association represents a type I error due to confound-
ing factors such as ethnicity and the influence of known
risk factors such as oral contraceptive use. Consequently,
it will be important to replicate our findings in larger pop-
ulation-based case-control studies.
Conclusion
We have identified a novel promoter polymorphism in
FANCA. It is unknown what biological effect the duplica-
tion might have but it may alter the basal rate of transcrip-
tion or the regulation of transcription. As FANCA is likely
to function as a tumour suppressor, it is plausible that
allelic variants with altered activity may modify cancer
risk. This pilot study has provided some evidence of an
association with ovarian cancer. Further studies to verify
this association are warranted as well as studies involving
predisposition to other cancers.
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